TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03820687

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Trial Educational Video
Description: Bilingual, culturally tailored educational video, low literacy booklet, and support from a patient navigator to empower new cancer patients to make informed decisions about cancer clinical trial participation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Trial Fact Sheet
Description: General Clinical Trial fact sheet with usual care information regarding Clinical Trials.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low literacy booklet
Description: A bilingual low-literacy booklet with educational content about clinical trials.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Navigator
Description: Support will be provided by a patient navigator to empower cancer patients to make an informed decision about cancer clinical trial participation by increasing awareness of clinical trials and MCC services, positive attitudes, and intentions to consider clinical trials as an appropriate treatment option for cancer.
Study: NCT06520293

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sweet Beverage
Description: A beverage containing different sweet ingredients.

Intervention type: OTHER
Group type: OTHER
Intervention: Sweet Beverage
Description: A beverage containing different sweet ingredients.

Intervention type: OTHER
Group type: OTHER
Intervention: Sweet Beverage
Description: A beverage containing different sweet ingredients.
Study: NCT05801835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (cytarabine: daunorubicin) liposome for injection
Description: Be given intravenously at 65U/m\^2 on days 1 and day3 of the first cycle of induction.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vyxeos
Description: Be given intravenously at 65U/m\^2 on days 1 and day3 of the first cycle of induction.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (cytarabine: daunorubicin) liposome for injection
Description: Be given intravenously at 65U/m\^2 on days 1 and day3 of the second cycle of induction.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vyxeos
Description: Be given intravenously at 65U/m\^2 on days 1 and day3 of the second cycle of induction.
Study: NCT04146428

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: clinician-mediated JASPER
Description: JASPER is a developmentally anchored behavioral intervention that assumes that communication develops from social interactions in which specific social engagement strategies, symbolic representations, and early communication forms are modeled and naturally reinforced by the adult's responses to the child. The adult referred in this condition is the clinician/therapist.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: parent-mediated JASPER
Description: JASPER is a developmentally anchored behavioral intervention that assumes that communication develops from social interactions in which specific social engagement strategies, symbolic representations, and early communication forms are modeled and naturally reinforced by the adult's responses to the child. The adult referred in this condition is the parent.
Study: NCT04119791

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: wild rice
Description: 30 grams of wild rice in the form salad, snack bar and soup
Study: NCT05025436

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupoint stimulation with low energy laser (Erger laser pen)
Description: Each subject was given the same main acupoints (5 acupoints) and physique matching acupoints (1-2 acupoints) interventional low-energy laser (Erger laser pen) acupoint stimulation, set wavelength 810nm +/-10%, The power is 200mW, and the Bahr parameter (B2: 1199 Hz; B3: 2398 Hz) module is selected according to the acupoints. The treatment time is 30 seconds per acupoint, and the treatment dose is 3 joules per acupoint three times a week. After a period of 4 weeks, after a 2-week pause, After the two groups crossed for 4 weeks, each subject was given the same main acupoints (5 acupoints) and physique matching acupoints (1-2 acupoints) with low-energy laser (Erjie laser pen) acupoint stimulation. Set wavelength 810nm +/-10%, power 200mW, select Bahr parameter (B2: 1199 Hz; B3: 2398 Hz) module according to acupoints, treatment time is 30 seconds per acupoint, and treatment dose is 3 joules per acupoint three times a week for a period of time 4 weeks.
Study: NCT05856136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl Injection
Description: Three different fentanyl doses (used for sedation) will be evaluated on their effects on shear wave elastography (SWE) and breathing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl Injection
Description: Three different fentanyl doses (used for sedation) will be evaluated on their effects on shear wave elastography (SWE) and breathing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl Injection
Description: Three different fentanyl doses (used for sedation) will be evaluated on their effects on shear wave elastography (SWE) and breathing
Study: NCT06103253

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: a Bla80 group
Description: the BLa80 group received 2.9 g of maltodextrin + 0.1 g of BLa80 bacterial powder 10B daily.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: a Bla80 group
Description: the BLa80 group received 2.9 g of maltodextrin + 0.1 g of BLa80 bacterial powder 10B daily.
Study: NCT06050044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group A (hyperbaric bupivacaine)
Description: Patients were injected intrathecally with 20 mg hyperbaric bupivacaine 0.5% solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group B (Mixture of Hyperbaric and Isobaric Bupivacaine)
Description: Patients received 10 mg hyperbaric bupivacaine and 10 mg isobaric bupivacaine 0,5 % solution
Study: NCT05311813

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Enoxaparin, Hydroxychloroquine
Description: To compare efficiency and safety of Enoxaparin and Hydroxychloroquine as monotherapy versus Polytherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin, Hydroxychloroquine
Description: To compare efficiency and safety of Enoxaparin and Hydroxychloroquine as monotherapy versus Polytherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin, Hydroxychloroquine
Description: To compare efficiency and safety of Enoxaparin and Hydroxychloroquine as monotherapy versus Polytherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin, Hydroxychloroquine
Description: To compare efficiency and safety of Enoxaparin and Hydroxychloroquine as monotherapy versus Polytherapy
Study: NCT04686032

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Advanced early Rehabilitation Program
Description: Patient education, Ambulation, In bed exercises, Deep breathing exercises: (5 rep x 3set), Connective tissue manipulation for intestinal motility (5 min) and TENS\* for incisional pain (30min)
Study: NCT04708236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORTD-1 low dose
Description: ORTD-1 will be administered intravenously once daily for 5 consecutive days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORTD-1 mid dose
Description: ORTD-1 will be administered intravenously once daily for 5 consecutive days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORTD-1 high dose
Description: ORTD-1 will be administered intravenously once daily for 5 consecutive days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle control
Description: Vehicle Control will be administered intravenously once daily for 5 consecutive days.
Study: NCT05750446

Intervention type: DRUG
Group type: OTHER
Intervention: Riociguat (BAY 63-2521)
Description: A selective stimulator of soluble guanylate cyclase (sGC)

Intervention type: DRUG
Group type: OTHER
Intervention: Riociguat (BAY 63-2521)
Description: A selective stimulator of soluble guanylate cyclase (sGC)

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Placebo
Study: NCT04684238

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Solution for Injection/Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoflurane
Description: Inhalation vapour, liquid. Isoflurane delivered by the AnaConDa-S (Anaesthetic Conserving Device)
Study: NCT05071768

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Focused ACT
Description: Brief acceptance and commitment therapy
Study: NCT04686032

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Early ambulation
Description: Patient education \& Assisted ambulation out of bed including walking away from bedside for at least 15 min gradually moving to Unsupervised ambulation for 30 min
Study: NCT04793256

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fluoride varnish (3M Clinpro White Varnish 5% sodium fluoride).
Description: 5% sodium fluoride Varnish is a fluoride varnish which is applied to tooth surfaces

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Resin based fissure sealant (3M Clinpro Sealant)
Description: teeth will be isolated with cotton rolls and saliva ejector than etching for pits and fissure sealant
Study: NCT05953727

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low level laser therapy with proprioceptive stimulation
Description: 10 minutes of low level laser therapy and 10-15 minutes of proprioceptive stimulation and 10 minutes of heating pack. Assessment and data collection will be done at baseline (initial), after 4 weeks of treatment protocol and patients will be followed up for the further 2 weeks to notice and report any change in condition and health status.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low level laser therapy without proprioceptive stimulation
Description: 10 minutes of low level laser therapy and 10 minutes of heating pack. Assessment and data collection will be done at baseline (initial), after 4 weeks of treatment protocol and patients will be followed up for the further 2 weeks to notice and report any change in condition and health status.
Study: NCT05022797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucarpidase 1000 UNT [Voraxaze]
Description: 2 vials of 1000 units per vial
Study: NCT04947670

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Renal arteriography followed by renal denervation
Description: Renal arteriography followed by renal denervation

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Renal arteriography
Description: Renal arteriography only
Study: NCT06493474

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: PEER ASSISTED BREASTFEEDING EDUCATION PROGRAM

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Care
Description: Non education program only routine care
Study: NCT06338956

Intervention type: DRUG
Intervention: LDL reduction therapy
Description: LDL reduction therapy

Intervention type: DRUG
Intervention: LDL reduction therapy
Description: LDL reduction therapy
Study: NCT05149105

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Argon plasma coagulation
Description: On D0, in the operating room, argon plasma coagulation will be performed around the perimeter of the anastomosis for a period of 5 to 10 min under general anesthesia. The removal of the catheter and the endoscope will be carried out under control. Patients will be kept under surveillance the night following the procedure. A liquid diet will be prescribed for 10 days. The follow-up will be carried out on an outpatient basis with a control endoscopy at 2 months, followed by a new procedure in the event of an anastomosis larger than 1.5 cm. A new endoscopic check will be carried out at 4 months if an argon plasma coagulation was performed during the previous check, with a third and last argon plasma coagulation if an anastomosis of more than 1.5 cm persists. The number of procedures will therefore be a maximum of 3. A control endoscopy will be performed at one year for the final control of the anastomosis.
Study: NCT06320587

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kangaroo care practice by both mother and father
Description: In this group, kangaroo care will be done by both mother and father. Mothers used the Mother-Infant Attachment Scale and the Perceived Maternal Parenting Self-Efficacy Scale as pretests; Fathers will also complete the Postpartum Father-Infant Attachment Survey and the Perceived Father Parenting Self-Efficacy Form. Mothers and fathers in the application group will be provided with kangaroo care for 45 minutes, 2 days a week for 5 weeks. The baby's vital signs will be monitored 30 minutes before each kangaroo care, at the 15th minute of each kangaroo care, and 30 minutes after the kangaroo care, and will be recorded on the Kangaroo Care Monitoring Form. After kangaroo care was completed at the end of 5 weeks, mothers used the Mother-Baby Attachment Scale and the Perceived Mother Parenting Self-Efficacy Scale as posttests; Postnatal Father-Infant Attachment Questionnaire and Perceived Father Parenting Self-Efficacy Form will be filled out by fathers.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Kangaroo care practice only mother
Description: In the control group, only the mother will care for the kangaroo. The application will be similar to the experimental group.
Study: NCT06062186

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 650 mg of placebo, given as two capsules containing maltodextrin

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AmaTea Guayusa Extract
Description: 650 mg of AmaTea Guayusa Extract, given as two capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lion's Mane
Description: 1000 mg of Lion's Mane, given as two capsules
Study: NCT05591664

Intervention type: DIAGNOSTIC_TEST
Intervention: eicosapentaenoic acid
Description: eicosapentaenoic acid levels of the groups will be monitored

Intervention type: DIAGNOSTIC_TEST
Intervention: eicosapentaenoic acid
Description: eicosapentaenoic acid levels of the groups will be monitored
Study: NCT04147104

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low flow ECCO2R
Description: Treatment with a medical device called ECCO2R. The device consists of a drainage cannula placed in a large central vein, a membrane lung (artificial gas exchanger), and a return cannula into the venous system. Blood is pumped through the membrane lung, and CO2 is removed by diffusion. A flowing gas known as sweep gas containing little or no CO2 runs along the other side of the membrane, ensuring a diffusion gradient from blood to the other side, hence promoting CO2 removal.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Invasive mechanical ventilation
Description: Invasive mechanical ventilation deviceto support acute respiratory failure and facilitate exhalation via an endotracheal tube or tracheotomy.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Invasive mechanical ventilation
Description: Invasive mechanical ventilation deviceto support acute respiratory failure and facilitate exhalation via an endotracheal tube or tracheotomy.
Study: NCT06534450

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: The patient's blood will not circulate through the apheresis machine. The patient will receive approximately 250 cc of normal saline during each sham pheresis procedure.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Plasma Exchange
Description: Blood is withdrawn from a peripheral or central vein into the blood cell separator which separates the whole blood into plasma and cell components. The plasma is removed and the blood cells are returned to the patient along with replacement fluids, most commonly 5% human albumin in normal saline.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Plasma Exchange
Description: Blood is withdrawn from a peripheral or central vein into the blood cell separator which separates the whole blood into plasma and cell components. The plasma is removed and the blood cells are returned to the patient along with replacement fluids, most commonly 5% human albumin in normal saline.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Plasma Exchange
Description: Blood is withdrawn from a peripheral or central vein into the blood cell separator which separates the whole blood into plasma and cell components. The plasma is removed and the blood cells are returned to the patient along with replacement fluids, most commonly 5% human albumin in normal saline.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IVIG
Description: Intravenous Immunoglobulin
Study: NCT04753827

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Drug eluting stent
Description: Put a Drug eluting stent in the blood vessel

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Drug eluting stent
Description: Put a Drug eluting stent in the blood vessel

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Drug eluting stent
Description: Put a Drug eluting stent in the blood vessel

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Durg coated balloon
Description: Put a Durg coated balloon in the blood vessel

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Durg coated balloon
Description: Put a Durg coated balloon in the blood vessel
Study: NCT05361772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: colchicine
Description: colchicine 0.5mg per day for 24 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo 0.5mg per day for 24 months
Study: NCT06519786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Patients will receive metformin immediate-release tablets orally for 24 weeks. Starting dose will be 500 mg once daily for all patients and the dose will be increased by 500 mg weekly until the goal dose is achieved (500 mg twice daily for patients \< 10 years of age, and 1000 mg twice daily for patients 10 years or older)
Study: NCT06519019

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dental Implant Surgery - Hydrophilic group
Description: A full thickness mucoperiosteal flap was elevated, under Local anaesthesia, osteotomy sites were prepared according to manufactures instructions, and parallel pin was used to confirm position and angulation of osteotomy site. One site received a hydrophilic implant and the other site received a conventional implant.~Ostell ISQ was used to measure primary stability of the dental implant. The surgical wound closure was with mattress and single interrupted sutures, using 4-0 vicryl suture.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dental Implant Surgery - Conventional group
Description: A full thickness mucoperiosteal flap was elevated, under Local anaesthesia, osteotomy sites were prepared according to manufactures instructions, and parallel pin was used to confirm position and angulation of osteotomy site. One site received a hydrophilic implant and the other site received a conventional implant.~Ostell ISQ was used to measure primary stability of the dental implant. The surgical wound closure was with mattress and single interrupted sutures, using 4-0 vicryl suture.
Study: NCT06440512

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dark chocolate Intervention
Description: The intervention involves daily consumption of 50 grams of dark chocolate for a period of two weeks. The dark chocolate is provided in tablet form, and participants are instructed to consume it daily.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dark chocolate Intervention
Description: The intervention involves daily consumption of 50 grams of dark chocolate for a period of two weeks. The dark chocolate is provided in tablet form, and participants are instructed to consume it daily.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White chocolate Intervention
Description: The intervention involves daily consumption of 40 grams of white chocolate for a period of two weeks. The dark chocolate is provided in tablet form, and participants are instructed to consume it daily.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White chocolate Intervention
Description: The intervention involves daily consumption of 40 grams of white chocolate for a period of two weeks. The dark chocolate is provided in tablet form, and participants are instructed to consume it daily.
Study: NCT06407180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone Acetonide
Description: receive intraarticular triamcinolone injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: receive intraarticular normal saline injection
Study: NCT05715970

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PoCT+questionnaire administration
Description: In Sicily, screening will be carried out in the general practitioner's clinics (GPs). GPs will have to submit the patients attending their clinics to the PoCT + software tools questionnaire. Subjects who are PoCT positive and/or who reach the minimum score in the questionnaire will be considered 'patients at risk of CD' and must be subjected, with prior consent, to in-depth diagnostics using standard serological methods. The subjects resulting positive in the serological investigations will then undergo the appropriate endoscopic and biopsy investigations to ascertain the presence of CD. In Malta the recruitment will exactly repeat the modalities already carried out in the ITAMA project, through the schools of Malta (Maltese takers), while the laboratory and endoscopic examinations of the subjects who tested positive for the PoCT and/or who will reach the minimum score in the software tools questionnaire will be centralized at the Mater Dei hospital.
Study: NCT06375109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: administered via Intravenous (IV) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin injection
Description: administered via IV injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin injection
Description: administered via IV injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin injection
Description: administered via IV injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin injection
Description: administered via IV injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide injection
Description: administered via IV injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide injection
Description: administered via IV injection